IL3RA and myelodysplastic syndrome: According to in vitro and pre-clinical in vivo data, one fully human anti-CD123 monoclonal antibody, KHK2823, was thought to be a promising anti-CD123 therapeutic therapy against AML, MDS and B-ALL [167].